EUCTR2020-005187-63-ES进行中（未招募）1 期
A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) - Phase II Nonalcoholic Steatohepatitis (NASH) study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Be able and willing to provide written informed consent to take part in the study and to comply with all the study’s requirements.
- •2. Be a man or woman =18 years of age at screening.
- •a. Histologic confirmation of NASH no more than 12 months before the screening visit date, demonstrating the existence of steatosis =5%, hepatocyte ballooning and chronic inflammation (at least 1 point for each component), and stage 1 through stage 3 liver fibrosis according to the NASH Clinical Research Network (CRN); OR
- •b. NAFLD based upon demonstration of at least 3 of the following 5 components of the metabolic syndrome below, at screening:
- •FPG =100 mg/dL (=5.6 mmol/L), or undergoing drug treatment for elevated plasma glucose concentrations
- •HDL-C concentration <40 mg/dL in male patients, or <50 mg/dL in female patients, or undergoing drug treatment for reduced serum HDL-C concentrations
- •Serum triglyceride (TG) concentration =150 mg/dL, or undergoing drug treatment for elevated serum TG concentrations
- •Waist circumference >102 cm in male patients or >88 cm in female patients
- •Systolic blood pressure =130 mm Hg or diastolic blood pressure =85 mm Hg, or undergoing drug treatment for hypertension, or antihypertensive drug treatment in a patient with a history of systemic hypertension
- •4. Serum ALT concentration >1 × ULN at screening
- •5. FIB-4 result >1.3 and =3.25, at screening:
- •If the FIB-4 result is =1.3 but =1.45, OR >2.67 and =3.25, the patient must undergo Fibroscan (VCTE) before proceeding to MRI studies.
- •The Fibroscan (VCTE) result must be >4 kPa but =12.5 kPa.
- •If such a Fibroscan (VCTE) result exists from the 3-month period before screening visit date, this result may be used.
- •6. Undergo MRI-PDFF that demonstrates =8% liver steatosis during the screening period.
- •7. Undergo MRI-MRE with a score =2.9 kPa during the screening period.
- •8. WOCBP must have a negative serum ß-human chorionic gonadotropin test result at screening.
- •Female patients must agree to use at least 1 highly effective birth control throughout the study and up to 30 days after the last dose of study drug has been taken. Highly effective contraception measures include the following options, but are not limited to:
- •Combined estrogen- and progestogen-containing hormonal contraception (administration may be oral, intravaginal, or transdermal);
- •Progestogen-only hormonal contraception associated with inhibition of ovulation (administration may be oral, injectable, or implantable);
- •Intrauterine device, intrauterine hormone-releasing system, bilateral tubal, occlusion (‘tubal occlusion’ includes ‘tubal ligation’);
- •Vasectomized partner (provided that the male has provided confirmation of surgical success and in the event that the vasectomized partner is the sole sexual partner of the woman of childbearing potential);
- •Sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk in relation to the duration of the clinical trial), only in the event that this is the preferred lifestyle of the patient.
- •Childbearing potential is defined as being fertile after menarche and until becoming postmenopausal unless permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
- •A postmenopausal state is defined as no menses for =12 consecutive months without an alternative medical cause.
- •Men with partners who are WOCBP must either be surgically sterile or agree to use a barrier contraceptive f
排除标准
- •1. Any patient who refuses to provide written informed consent to take part in the study, and/or appears unwilling to comply with study-specific requirements
- •2. Female persons who are pregnant or are breastfeeding at screening, or who plan to become pregnant during the study
- •3. BMI <25 kg/m2
- •4. Any of the laboratory test abnormalities at screening (see the list in the protocol section 8.2 Exclusion Criteria)
- •5. Chronic liver disease other than confirmed NASH or NAFLD, including but not limited to the diagnoses/entities (see the list in the protocol section 8.2 Exclusion Criteria)
- •6. Medical, histologic, and/or imaging history of hepatic cirrhosis
- •7. Clinical, endoscopic, imaging and/or laboratory manifestations of portal hypertension, such as spider nevi, splenomegaly, clinically evident ascites formation, nonbleeding gastro-oesophageal varices
- •8. Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) related illness
- •9. Chronic use (=12 months) of any drug known to be associated with development of NAFLD during the 5 years before the anticipated Day 1 visit date (eg, amiodarone, methotrexate, systemic glucocorticoids [unless employed at physiologic replacement doses for management of confirmed adrenal insufficiency], tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement therapy, anabolic steroids [other than testosterone replacement preparations being taken at a physiologic replacement dose for management of confirmed male hypogonadism], sodium valproate, and other hepatotoxins such as minocycline)
- •10. Use of the medications (see the list in the protocol section 8.2 Exclusion Criteria)
- •11. History of significant alcohol consumption, defined as an average of >20 g/day in female patients and >30 g/day in male patients, for a period of >3 consecutive months within 1 year before screening, hazardous alcohol use (Alcohol Use Disorders Identification Test score =8), or an inability to reliably quantify alcohol consumption based upon judgment of the investigator
- •12. Use of legally prohibited substance or substances within 1 year before the screening visit date in a manner that may jeopardize the patient’s willingness and/or ability to complete study requirements, in the judgment of the investigator.
- •13. Weight change =7% within the 6 months before screening or =5% within the 3 months before screening
- •14. Prior or planned (during the study period) weight reduction surgery (eg, sleeve gastrectomy, Roux-en-Y gastrojejunostomy)
- •15. Type 1 diabetes mellitus by medical history
- •16. Poorly controlled type 2 diabetes mellitus (this is defined as HbA1c >9.5% at screening, or a patient whose oral antidiabetic medication dosing requires adjustment >10% less than 2 months before the screening visit date).
- •17. Uncontrolled systemic hypertension (either treated or untreated) defined as systolic blood pressure >160 mm Hg or a diastolic blood pressure >100 mm Hg at screening. A retest of blood pressure, (after establishing good blood pressure control within a reasonable period of time and up to the Baseline visit) is permissible at the discretion of the investigator
- •18. Patients who demonstrate recent evidence (within 6 months of the anticipated date of the Day 1 visit) of clinically evident and significant atheromatous cardiovascular disease (eg, unstable angina, acute coronary syndrome, myocardial infarction, cerebrovascular accident [stroke], cerebrovascular ischemia, transien
研究者
相似试验
进行中（未招募）
1 期
A study investigating the safety, absorption and elimination of FM101, a new compound in the treatment of non-alcoholic fatty liver disease.onalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)MedDRA version: 22.0Level: LLTClassification code 10029530Term: Non-alcoholic fatty liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-005187-63-HUFuture Medicine Co., Ltd.60
进行中（未招募）
不适用
A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-650032) versus Pegasys administered with Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) administered with or without Ribavirin plus 2 direct antiviral agents (BMS 790052 and BMS-650032) (Part B) in chronic hepatitis C genotype-1 treatment na?ve subjects + Administrative Letter 01 (version 1.0, dated 10-Jan-11) - The D-LITE Study:Direct Antiviral Agents plus Lambda Interferon Treatment EvaluatioChronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912EUCTR2010-022568-11-ITBristol-Myers Squibb International Corporation200
进行中（未招募）
不适用
Phase 2 Safety Study of Pegylated Interferon Lambda plus single or 2 Direct Antiviral Agents with RibarviriEUCTR2010-022568-11-DEBristol Myers Squibb International Corporation200
进行中（未招募）
1 期
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabColorectal CancerCTIS2023-505110-14-00AbbVie Deutschland GmbH & Co. KG206
进行中（未招募）
1 期
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)EUCTR2016-001657-41-DEAbbVie Deutschland GmbH & Co. KG90